More Stories

Informist, Tuesday, Aug. 4, 2026

By Ayush Jaiswal

MUMBAI - Robust growth in volumes and a rise in realisations are expected to boost the June quarter revenues and net profit of diagnostic lab

Metropolis Healthcare Ltd., according to brokerages tracking the company.

Metropolis' consolidated net profit for the June quarter is expected to grow 21% on year to INR 547 million, according to the average of estimates from 10 brokerages. Sequentially, this will be up 8% from INR 508 million. The highest estimate for the company's net profit is INR 579 million from Yes Securities (India) Ltd. and the lowest is INR 522 from PhillipCapital (India) Pvt. Ltd.

The company's June quarter revenue is expected at INR 4.45 billion, up 15% on year and 5% on quarter, according to the estimates. The highest estimate for the company's net sales is INR 4.49 billion from ICICI Securities Ltd. and the lowest is INR 4.41 billion from PhillipCapital.

In an update, Metropolis has reported a revenue growth of nearly 16% on year for the June quarter, driven by patient volumes and realization benefits due to product mix change. The company's TruHealth Wellness and Specialty segments grew the fastest in the quarter. The business-to-consumer segment registered healthy volume growth, driven by increased throughput from the expanded center network. The company's business-to-business volumes also grew, supported by higher wallet share and new customer acquisition, backed by improved service quality and delivery levels, the company said.

Metropolis' patient volume is expected to grow 8% on year, Emkay said. The ramp-up in acquired entities, such as Scientific Pathology, Dr. Ahuja's Pathology & Imaging Center, and Dr. RS Patil's Ambika Pathology Laboratory will also aid revenue growth for the quarter.

The diagnostics sector's revenue is expected to grow 17% on year, driven by 11% on year growth in test volumes, Antique Stock Broking said. The volume growth will be driven by network expansion, higher patient footfalls, and continued traction in preventive wellness offerings, the brokerage added. The industry's realisations would be aided by higher share of specialised or bundles tests. The sector is expected to report a robust quarter on the back of a stable pricing environment and rising awareness of preventive testing, Emkay said.

Healthcare service providers are strengthening their presence across non-metro markets while focusing on improving the productivity of existing labs, centres, and pickup points, ICICI Securities said.

Metropolis' earnings before interest, tax, depreciation, and amortisation are expected to grow 25% on year to INR 1.12 billion, according to the average of estimates from nine brokerages. The highest estimate for the company's EBITDA is INR 1.18 billion from Yes Securities and the lowest is INR 1.08 from PhillipCapital.

The company's June quarter EBITDA margin is expected to expand 130-213 basis points from 23.2 reported in the year-ago quarter, led by an improvement in the margins of the standalone business and acquired entities, according to brokerages.

Metropolis Healthcare offers a comprehensive range of clinical laboratory tests and profiles. It owns a chain of diagnostic centres across India, South Asia, Africa, and the Middle East. The company will detail its June quarter earnings Tuesday. Investors will watch for specialty mix, realisation growth, expansion of mini-hubs and collection centres, integration of core diagnostics, and management commentary on sustainability or margin, Antique said. Further, investors will also watch for price hikes and inorganic expansion in the financial year 2026-27 (Apr-Mar), Emkay said.

At 1052 IST, shares of Metropolis Healthcare were traded at INR 589.85 per share on the National Stock Exchange, down over 1% from Monday. The company's shares are up almost 9% since it announced its March quarter earnings on May 13.

All the six brokerage reports on the company available with Informist have a "buy" recommendation on the stock with an average target price of INR 610 per share. This is 3% higher than the current market price.

The following are the Apr-Jun earnings estimates for Metropolis Healthcare from nine brokerages, in descending order of the estimates of net profit, in INR million:

End

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

Edited by Pankaj Aher

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.